AZ Divests Arimidex And Casodex Rights To Juvisé
Banks Upfront Payment Of $181m
Executive Summary
Selling off the two cancer drugs to the French firm is the latest example of AstraZeneca's strategy of reducing its portfolio of mature assets to boost its R&D budget.
You may also be interested in...
AZ Gets IBD Drug Back From Allergan
Allergan is selling its Crohn’s disease and ulcerative colitis drug brazikumab back to AstraZeneca to satisfy regulators ahead of its link-up with AbbVie, essentially giving the asset to the UK major for free.
Deal Watch: Pfizer Licenses Skin-Targeted JAK Inhibitor Portfolio From Theravance
Deal with Pfizer makes for Theravance’s third large pharma partnership since 2016. AbbVie off-loads Marinol to India’s Alkem, Bausch licenses candidate for rare form of dry eye disease from Novaliq.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.